This inventor holds 4 USPTO granted patents. Top assignees: Cetus Corporation, Cetus Oncology Corporation. Active years: 1988-1993.
Location History:
- Oakland, CA (US) (1988 - 1990)
- San Bruno, CA (US) (1990 - 1993)
Company Filing History:
Years Active: 1988-1993
Title: The Innovations of Michael J Knauf
Introduction
Michael J Knauf is a notable inventor based in San Bruno, California. He has made significant contributions to the field of biotechnology, particularly in the development of interleukin-2 muteins and their applications. With a total of 4 patents, his work has had a considerable impact on pharmaceutical compositions and therapeutic methods.
Latest Patents
One of his latest patents involves the creation of interleukin-2 muteins and polymer conjugation thereof. This innovation focuses on muteins of IL-2, where one of the amino acids in the native sequence is replaced by a cysteine residue. These muteins are conjugated to polymers such as polyethylene glycol homopolymers, enhancing their therapeutic potential. Another significant patent is for succinylated interleukin-2 for pharmaceutical compositions. This composition allows biologically active conjugated interleukin-2 to be dissolved in an aqueous carrier medium without the need for a solubilizing agent, making it more effective for medical applications.
Career Highlights
Throughout his career, Michael J Knauf has worked with prominent companies in the biotechnology sector, including Cetus Corporation and Cetus Oncology Corporation. His experience in these organizations has contributed to his expertise in the development of innovative biopharmaceuticals.
Collaborations
Michael has collaborated with several professionals in his field, including Nandini Katre and Robert J Goodson. These collaborations have likely enriched his research and development efforts, leading to advancements in his patented technologies.
Conclusion
Michael J Knauf's contributions to biotechnology through his patents and collaborations highlight his role as an influential inventor. His work continues to pave the way for advancements in therapeutic applications of interleukin-2.